Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyAlison Stopeck, Ada Braun, Allan Lipton et al.|Journal of Clinical Oncology|2010Cited by 1.6k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Susie Jun, Karim Fizazi et al.|European Journal of Cancer|2012Cited by 588
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Laura M. Spring et al.|Cancer Discovery|2021Cited by 241
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison Stopeck, Ada Braun, Karim Fizazi et al.|Supportive Care in Cancer|2015Cited by 190
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsAllan Lipton, Ada Braun, Karim Fizazi et al.|European Journal of Cancer|2015Cited by 114